Mary Katherine Ladone's most recent trade in Novanta Inc was a trade of 572 Common Stock done . Disclosure was reported to the exchange on July 11, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Novanta Inc | Mary Katherine Ladone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2025 | 572 | 572 (0%) | 0% | - | Common Stock | |
| Novanta Inc | Mary Katherine Ladone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2025 | 572 | 0 | - | - | Restricted Stock Units | |
| Bioventus Inc Ordinary Shares | Mary Katherine Ladone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2025 | 32,282 | 32,282 | - | - | Restricted Stock Units | |
| Bioventus Inc Ordinary Shares | Mary Katherine Ladone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2025 | 26,493 | 78,981 (0%) | 0% | 0 | Class A Common Stock | |
| Bioventus Inc Ordinary Shares | Mary Katherine Ladone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jun 2025 | 26,493 | 0 | - | - | Restricted Stock Units | |
| Inogen Inc | Mary Katherine Ladone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 30,612 | 76,885 (0%) | 0% | 0 | Common Stock | |
| Novanta Inc | Mary Katherine Ladone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 1,325 | 1,325 | - | - | Restricted Stock Units | |
| Novanta Inc | Mary Katherine Ladone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2024 | 572 | 572 | - | - | Restricted Stock Units | |
| Bioventus Inc Ordinary Shares | Mary Katherine Ladone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 1,814 | 0 | - | - | Restricted Stock Units | |
| Bioventus Inc Ordinary Shares | Mary Katherine Ladone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2024 | 1,814 | 52,488 (0%) | 0% | 0 | Class A Common Stock | |
| Bioventus Inc Ordinary Shares | Mary Katherine Ladone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 26,493 | 26,493 | - | - | Restricted Stock Units | |
| Bioventus Inc Ordinary Shares | Mary Katherine Ladone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 30,400 | 0 | - | - | Restricted Stock Units | |
| Bioventus Inc Ordinary Shares | Mary Katherine Ladone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2024 | 30,400 | 50,674 (0%) | 0% | 0 | Class A Common Stock | |
| Inogen Inc | Mary Katherine Ladone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 21,871 | 46,273 (0%) | 0% | 0 | Common Stock |